AION Labs Overview
AION Labs is a first-of-its-kind venture studio formed by leading global pharma companies, technology giants, and top-tier investors. AION Labs mission is to create and adopt AI technologies that will transform the process of drug discovery and development for the betterment of human health. AION Labs partners include AstraZeneca, Merck, Pfizer, Teva, the Israel Biotech Fund, Amiti Ventures, and AWS, supported by BioMed X and the Israeli Innovation Authority. Based in Rehovot, near the Weizmann Institute of Science, at the heart of Israel’s vibrant biotech ecosystem. AION Labs fosters innovation through a unique venture studio model, creating startups that bridge global pharmaceutical expertise with advanced AI and biotechnology. Their venture studio model reduces risk by facilitating cross-industry partnerships, enabling seamless data sharing, and offering unparalleled access to pharma R&D expertise. This allows startups to fast-track their path to market, enabling them to create and validate transformative solutions for the biotech industry. AION Labs’ company creation process, through both the AION Building and AION Seeding tracks, addresses unmet industry needs through a rigorous validation process. Both tracks provide funding and unparalleled access to pharma R&D expertise, differing in development stages and technology maturity.
Latest News
growth-positive
/PRNewswire/ -- AION Labs, the first-of-its-kind venture studio spearheading the adoption of AI technologies and computational science to solve therapeutic...
AION Labs, a venture studio in Israel, is launching a global call for applications to form a new startup focused on developing an AI-driven computational platform for identifying molecular target combinations for multispecific biologic drugs. The initiative, supported by partners like AstraZeneca, Merck, Pfizer, and others, aims to revolutionize drug discovery by integrating AI to enhance the identification of therapeutic strategies. The platform will prioritize novel combinations based on disease relevance and biomarker predictability, potentially transforming biologic drug design. AION Labs is seeking global talent in computational biology, AI, and biomedical science to join this innovative venture.
PartnersProduct Stage
Inside AION Labs, the AI-focused venture studio with the backing of AstraZeneca, Pfizer, AWS and other power players
growth-positive
AION Labs Launches New AI Startup to Accelerate Identification of Active Small Molecules for Drug Discovery
ProPhet, a new startup launched by AION Labs, aims to revolutionize drug discovery by leveraging AI to identify active small molecules for drug targets. The company addresses the need to accelerate and enhance early drug discovery stages by targeting proteins with limited information. ProPhet uses advanced machine learning technologies to optimize novel algorithms, making the drug discovery process more efficient. AION Labs, comprising partners like AstraZeneca, Merck, Pfizer, and others, provides ProPhet with resources and connections to succeed. The venture studio focuses on adopting AI technologies to transform drug discovery and development.
Partners
growth-positive
AION Labs, In Continued Partnership with BioMed X, Launches First 2024 Global Call for Applications: AI/ML Platform for Targeting RNA with Small Molecules
AION Labs, a venture studio comprising AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund, Amiti Ventures, and Amazon Web Services (AWS), is seeking global research and technology talent to form a new startup. The startup will focus on the development of an AI/ML computational platform to identify functional regions in RNA that can be targeted with small molecules. The technology developed will be evaluated using a selected RNA target as a proof-of-concept. The company is inviting global computational biologists, bioinformatics scientists, AI and machine learning professionals, and experts in RNA biology and structure to propose the development of an RNA-specific computational platform.
PartnersExpand
growth-positive
How AI And Machine Learning Are Transforming Drug Discovery and Development
AION Labs, an innovation lab created by a consortium of leading pharmaceutical companies and tech investors, aims to leverage AI and computational sciences to transform the pharmaceutical industry. The lab plans to create 20 to 25 new companies in the pharma AI space within the next five years. The digitization of the drug discovery process and the need for tech solutions to handle patient data have created an opportunity for Israel to become a hub for pharmaceutical innovation, similar to its success in the autonomous vehicle marketplace. The challenges in the pharma industry include identifying the right problems to solve, accessing private data, validating technology, and developing the right business models. Collaboration between pharma companies and technology companies is crucial to overcome these challenges.
InvestmentAcquisitionPartners
Team Members
6
Web & Social Links
| Website | www.aionlabs.com/ |
Locations
Rehovot, Israel
Photos & Videos
2 item(s)
AION Labs Business
Business models
—
Product stage
—
Employees
—
Sector
—Target Customer
—Core Technology
—Tags (14)
machine-learningincubatorproteinsbioconvergencedrug-developmentpharma-companiesdeep-learningprecision-medicinepharmaceuticalstherapeuticsdrug-discoverybiotechnologyartificial-intelligencebiopharmaceuticalAION Labs Financials
—
Total funding
—
Capital raised
—
Last funding
—
Funding stage
—
Total rounds
—
Investors
AION Labs Lifecycle
AION Labs News
12 articles
growth-positive
/PRNewswire/ -- AION Labs, the first-of-its-kind venture studio spearheading the adoption of AI technologies and computational science to solve therapeutic...
AION Labs, a venture studio in Israel, is launching a global call for applications to form a new startup focused on developing an AI-driven computational platform for identifying molecular target combinations for multispecific biologic drugs. The initiative, supported by partners like AstraZeneca, Merck, Pfizer, and others, aims to revolutionize drug discovery by integrating AI to enhance the identification of therapeutic strategies. The platform will prioritize novel combinations based on disease relevance and biomarker predictability, potentially transforming biologic drug design. AION Labs is seeking global talent in computational biology, AI, and biomedical science to join this innovative venture.
PartnersProduct Stage
Inside AION Labs, the AI-focused venture studio with the backing of AstraZeneca, Pfizer, AWS and other power players
growth-positive
AION Labs Launches New AI Startup to Accelerate Identification of Active Small Molecules for Drug Discovery
ProPhet, a new startup launched by AION Labs, aims to revolutionize drug discovery by leveraging AI to identify active small molecules for drug targets. The company addresses the need to accelerate and enhance early drug discovery stages by targeting proteins with limited information. ProPhet uses advanced machine learning technologies to optimize novel algorithms, making the drug discovery process more efficient. AION Labs, comprising partners like AstraZeneca, Merck, Pfizer, and others, provides ProPhet with resources and connections to succeed. The venture studio focuses on adopting AI technologies to transform drug discovery and development.
Partners
growth-positive
AION Labs, In Continued Partnership with BioMed X, Launches First 2024 Global Call for Applications: AI/ML Platform for Targeting RNA with Small Molecules
AION Labs, a venture studio comprising AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund, Amiti Ventures, and Amazon Web Services (AWS), is seeking global research and technology talent to form a new startup. The startup will focus on the development of an AI/ML computational platform to identify functional regions in RNA that can be targeted with small molecules. The technology developed will be evaluated using a selected RNA target as a proof-of-concept. The company is inviting global computational biologists, bioinformatics scientists, AI and machine learning professionals, and experts in RNA biology and structure to propose the development of an RNA-specific computational platform.
PartnersExpand
growth-positive
How AI And Machine Learning Are Transforming Drug Discovery and Development
AION Labs, an innovation lab created by a consortium of leading pharmaceutical companies and tech investors, aims to leverage AI and computational sciences to transform the pharmaceutical industry. The lab plans to create 20 to 25 new companies in the pharma AI space within the next five years. The digitization of the drug discovery process and the need for tech solutions to handle patient data have created an opportunity for Israel to become a hub for pharmaceutical innovation, similar to its success in the autonomous vehicle marketplace. The challenges in the pharma industry include identifying the right problems to solve, accessing private data, validating technology, and developing the right business models. Collaboration between pharma companies and technology companies is crucial to overcome these challenges.
InvestmentAcquisitionPartners
growth-positive
AION Labs, Powered by BioMed X, Launches Third Global Call for Application: Artificial Intelligence for Design and Optimization of Antibodies for Targeted Therapies
AION Labs and BioMed X have launched a global call for applications to identify biomedical scientists and inventors to form a new startup at AION Labs headquarters in Israel. The chosen startup team will be sponsored by industry-leading partners and supported by the Israel Innovation Authority and Digital Israel office. AION Labs is seeking to develop a next-generation computational platform using AI to optimize antibodies for targeted therapies. The goal is to improve the design and optimization of antibodies, reducing cycle times and attrition rates. Interested candidates can apply through the BioMed X Career Space before April 10, 2022.
PartnersInvestment
growth-positive
AION Labs, Powered by BioMed X, Launches Second Global Call for Application: Artificial Intelligence for Clinical Trial Readiness of Drug Candidates
AION Labs and BioMed X have announced the launch of a global call for applications to form a new startup at AION Labs headquarters in Israel. The chosen startup team will be sponsored by industry-leading partners and supported by the Israel Innovation Authority and Digital Israel office. AION Labs is seeking the development of a computational platform that can improve the success rate of drug candidates in clinical trials. Computational biologists, AI researchers, and biomedical scientists are invited to propose innovative ideas. The selected team will receive resources, mentorship, and incubation for up to four years. Interested candidates can apply through the BioMed X Career Space before February 13, 2022.
Partners
growth-positive
Big pharma finds Israel's drug development role
AION Labs, a joint project by pharmaceutical companies Teva, Merck Serono, Pfizer, and AstraZeneca, biotech investment fund IBF, and Amazon Web Services (AWS), is set to change the biomed industry in Israel. The incubator, which focuses on the development of future drugs based on digital computing capabilities, has been praised for its innovative approach and successful collaboration between Israeli research and leading global companies. The initiative is expected to attract more international pharmaceutical companies to Israel and boost the countrys biomed industry.
PartnersInvestmentExpand
growth-positive
AION Labs, Powered by BioMed X, Launches First Global Call for Application: Artificial Intelligence for Antibody Design
AION Labs and BioMed X have launched a global call for applications to identify biomedical scientists and inventors to form a new startup at AION Labs headquarters in Rehovot, Israel. The chosen startup team will be sponsored by industry-leading partners and supported by the Israel Innovation Authority. AION Labs is inviting computational biologists and biomedical scientists to propose the development of a computational platform for antibody discovery. The winning team will receive resources and mentorship during a fully-funded incubation period of up to four years. Interested candidates can apply before December 12, 2021.
PartnersInvestment
growth-positive
AION Labs, Biotech Innovation Lab Launched by Top Pharma, Tech and Investment Leaders
AION Labs, an innovation lab spearheading the adoption of AI technologies and computational science in the pharmaceutical industry, has officially launched. The lab is a consortium of four leading pharmaceutical companies (AstraZeneca, Merck, Pfizer, and Teva) and two leaders in the hi-tech and biotech investment sphere (Amazon Web Services Inc. and Israel Biotech Fund). AION Labs aims to create and invest in early-stage start-ups focused on AI and computational biology in drug discovery and development. The lab will leverage the power of artificial intelligence and the cloud to accelerate the discovery of new treatments. Mati Gill has been appointed CEO of AION Labs, and the lab has also announced a strategic partnership with BioMed X. The lab will include both wet lab and cloud-based computational lab environments.
PartnersInvestment
growth-positive
Pharma consortium, AWS open Israel AI therapeutics lab
AstraZeneca, Merck, Pfizer, and Teva have partnered with AWS and IBF to open AION Labs, an innovation lab focused on AI technologies and computational science in drug discovery. The lab, based in Rehovot, Israel, will invest in early-stage startups and provide resources and mentorship to develop new technologies in the pharmaceutical industry. AION Labs aims to accelerate the discovery of new treatments, improve efficiency, and advance precision medicine. The consortium won a tender from the Israel Innovation Authority, and the lab will be supported by the Israeli government. AION Labs has also formed a strategic partnership with BioMed X. The article highlights the potential of AI, data analytics, and collaboration in transforming the pharmaceutical R&D process.
PartnersInvestment
growth-positive
Pfizer, AstraZeneca, Merck, and Teva win tender for new Israeli Innovation Lab
The Israel Innovation Authority (IIA) and the National Digital Ministry have selected Pfizer, AstraZeneca, Merck, and Teva to establish an Innovation Lab to research digital health and computational biology. The lab will be located at Rehovot Science Park and aims to help entrepreneurs and startups in the healthcare industry. The lab has a government budget of $9.9 million and additional funding from its partners. It is part of the Bio-convergence Strategy to advance AI-based computational technologies in healthcare.
PartnersInvestment
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
AION Labs Internal
Recent Updates
Ayelet Levi Shinebox
· yayhosh@gmail.com · Manual · 2023-08-06 07:02:54.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2025-01-19 13:07:51.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2025-01-19 13:19:25.000000
Sharon Gour Arie
· sharonarie@aionlabs.com · Manual · 2025-01-15 14:37:53.000000
Doron Bobman
· doron.b@sncentral.org · Manual · 2024-12-18 09:12:10.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2024-02-04 14:18:32.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2025-01-19 13:22:19.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2025-01-19 13:08:09.000000
Doron Bobman
· doron.b@sncentral.org · Manual · 2024-12-18 09:11:53.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2024-02-04 14:18:20.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2025-01-19 13:00:45.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2024-02-04 14:18:10.000000
Ayelet Levi Shinebox
· yayhosh@gmail.com · Manual · 2023-08-06 07:02:54.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2025-01-19 13:03:00.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2025-01-19 13:00:44.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2025-01-19 13:03:01.000000
Ortal Wein
· ortalw@sncentral.org · Automatic · 2024-02-04 14:18:10.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2024-02-04 14:19:10.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2025-01-19 13:08:09.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2025-01-19 13:03:00.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2025-01-19 12:59:10.000000
Doron Bobman
· doron.b@sncentral.org · Manual · 2024-12-18 09:12:10.000000
Ayelet Levi Shinebox
· yayhosh@gmail.com · Manual · 2023-08-06 07:03:08.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2025-01-19 13:03:00.000000
Doron Bobman
· doron.b@sncentral.org · Manual · 2024-12-18 09:11:52.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2025-01-19 13:02:58.000000
Doron Bobman
· doron.b@sncentral.org · Manual · 2024-12-18 09:11:53.000000
Ortal Wein
· ortalw@sncentral.org · Automatic · 2024-02-04 14:18:10.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2025-01-19 13:04:24.000000
Ayelet Levi Shinebox
· yayhosh@gmail.com · Manual · 2023-08-06 07:03:08.000000
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 57/100 |
| Missing | funding stage, product stage, sector, number of employees, business model, tag line, funding rounds, markets |
| BI Verification | Matan Eblagon |
| Registrar ID | 516263316 |
| Crunchbase | aion-labs |
| Creator | Yotam Maman |
| Creator email | yotamm1988@gmail.com |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2025-01-19T00:00:00.000Z |
| Created | 2021-10-14T00:00:00.000Z |